bay-1217389
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Feb 27, 2015 (NCT02366949)
Timeline
2010s
- Jan 1, 2015
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Dual specificity protein kinase TTKINHIBITOR
TTK inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
COc1ccc(Oc2cc(NCCC(F)(F)F)c3ncc(-c4ccc(C(=O)NC5CC5)c(C)c4)n3n2)c(F)c1F- Mol. weight
- 561.51 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4456085 ↗
- ChEMBLCHEMBL3544955 ↗
Also known as
- bay 1217389
- bay 1217389
- bay-1217389
- bay-1217389
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02366949 | Phase 1 | Feb 27, 2015 | Bayer |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bayer | For profit | 1 | 1 | 1 | 2015 |
1 organizations
Page 1 / 1